Abstract
In June 2013, the European Medicine Agency recommended limiting codeine use in paediatric patients, creating a void in managing moderate pain. We reviewed the literature published in English (1985-June 2017) on the pharmacokinetic, pharmacodynamic and safety profile of ketorolac, a possible substitute for codeine and opioids, for treating moderate-to-severe pain. We found that gastrointestinal side effects were mainly reported with prolonged use, significant bleeding was reported in adenotonsillectomy, and adverse renal effects appeared to be limited to patients with specific coexisting risk factors.
CONCLUSION: The short-term use of ketorolac appears to be safe for children in many situations.
| Original language | English |
|---|---|
| Journal | Acta Paediatrica, International Journal of Paediatrics |
| DOIs | |
| Publication status | E-pub ahead of print - Dec 16 2017 |
Fingerprint
Cite this
Narrative review shows that the short-term use of ketorolac is safe and effective in the management of moderate-to-severe pain in children. / Marzuillo, Pierluigi; Calligaris, Lorenzo; Amoroso, Stefano; Barbi, Egidio.
In: Acta Paediatrica, International Journal of Paediatrics, 16.12.2017.Research output: Contribution to journal › Review article
}
TY - JOUR
T1 - Narrative review shows that the short-term use of ketorolac is safe and effective in the management of moderate-to-severe pain in children
AU - Marzuillo, Pierluigi
AU - Calligaris, Lorenzo
AU - Amoroso, Stefano
AU - Barbi, Egidio
N1 - ©2017 Foundation Acta Paediatrica. Published by John Wiley & Sons Ltd.
PY - 2017/12/16
Y1 - 2017/12/16
N2 - In June 2013, the European Medicine Agency recommended limiting codeine use in paediatric patients, creating a void in managing moderate pain. We reviewed the literature published in English (1985-June 2017) on the pharmacokinetic, pharmacodynamic and safety profile of ketorolac, a possible substitute for codeine and opioids, for treating moderate-to-severe pain. We found that gastrointestinal side effects were mainly reported with prolonged use, significant bleeding was reported in adenotonsillectomy, and adverse renal effects appeared to be limited to patients with specific coexisting risk factors.CONCLUSION: The short-term use of ketorolac appears to be safe for children in many situations.
AB - In June 2013, the European Medicine Agency recommended limiting codeine use in paediatric patients, creating a void in managing moderate pain. We reviewed the literature published in English (1985-June 2017) on the pharmacokinetic, pharmacodynamic and safety profile of ketorolac, a possible substitute for codeine and opioids, for treating moderate-to-severe pain. We found that gastrointestinal side effects were mainly reported with prolonged use, significant bleeding was reported in adenotonsillectomy, and adverse renal effects appeared to be limited to patients with specific coexisting risk factors.CONCLUSION: The short-term use of ketorolac appears to be safe for children in many situations.
U2 - 10.1111/apa.14189
DO - 10.1111/apa.14189
M3 - Review article
C2 - 29247538
JO - Acta Paediatrica, International Journal of Paediatrics
JF - Acta Paediatrica, International Journal of Paediatrics
SN - 0803-5253
ER -